Targeted delivery of anti-HIV drugs to the gut
A targeted anti-HIV drug delivery to the GALT
This study is exploring a new way to help deliver HIV medications directly to the gut, where the virus can hide, using tiny particles that target special cells in the gut to make the treatment work better for people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Rio Grande Valley NIH-funded |
| Lab location | 1 site (Edinburg, United States) |
| Project ID | NIH-10857273 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to deliver anti-HIV drugs specifically to the gut-associated lymphoid tissue (GALT), where the virus can hide and persist despite treatment. The approach involves creating a specialized nanomedicine that uses M-cells, which are unique cells in the gut that can transport drugs effectively. By bio-conjugating the nanodrug with antibodies that target M-cells, the researchers aim to enhance the delivery and effectiveness of existing anti-HIV medications. This could lead to a more sustained and effective treatment for patients living with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have not achieved complete viral suppression with current antiretroviral therapies.
Not a fit: Patients who are not living with HIV or those who have already achieved complete viral suppression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for HIV patients by effectively targeting and eradicating viral reservoirs in the gut.
How similar studies have performed: While targeted drug delivery is a novel approach in HIV treatment, similar strategies in other diseases have shown promising results, indicating potential for success in this area.
Where this research is happening
Edinburg, United States
- University of Texas Rio Grande Valley — Edinburg, United States (Active)
Researchers
- Principal investigator: Roy, Upal — University of Texas Rio Grande Valley
- Study coordinator: Roy, Upal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.